Skip to main content

Dipeptidyl peptidase-4 (DPP-4) inhibitors

medwireNews top story

Further support for early combination therapy in type 2 diabetes

VERIFY trial results

Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.

Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Sulfonylurea pill

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

medwireNews top story

PIONEER 3: Oral semaglutide proves worth against sitagliptin

Pills in hand

Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.

medwireNews editor's pick

Possible bile duct cancer risk with incretin-based medications

Mixed pills

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Journal article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Doctor holding defibrillator (symbolic image with model)

The authors assess the risk of hospitalization due to HF with the use of dipeptidyl peptidase-4 inhibitors compared to glucagon like peptide-1 receptor agonists [read more].
Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

Get more on:  Diabetic complications | Medication | Type 2 diabetes

Journal article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Smiling doctors

We present one successful case that demonstrates a significantly beneficial effect of physical exercise and lifestyle intervention in the management of type 2 diabetes mellitus [read more].
Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

Get more on: Type 2 diabetes | Physical activity | Lifestyle interventions​​​​​​​

Journal article

Glycemic impact of non-nutritive sweeteners: A systematic review and meta-analysis of randomized controlled trials

Person holding sweeteners

A systematic review and meta-analysis of randomized controlled trials was conducted to quantitatively synthesize existing scientific evidence on the glycemic impact of non-nutritive sweeteners [read more].
Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

Get more on: Type 2 diabetes | Glycemic control | Diet and nutritional management

medwireNews editor's pick

Modern antidiabetic medications ranked for survival benefits

Mixed diabetes medications

A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.

Journal article

Safety and efficacy of teneligliptin in patients with type 2 diabetes mellitus and impaired renal function: Interim report from post-marketing surveillance

Kidneys diagram

In this interim analysis, we evaluated the long-term safety and efficacy of teneligliptin in a subgroup of type 2 diabetes patients with renal impairment using case report forms [read more].
Haneda M et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0416-2

Get more on: Type 2 diabetesDPP-4 inhibitors | Glycemic control

medwireNews editor's pick

Support for alogliptin as add-on therapy for type 2 diabetes


Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.


07-31-2020 | Ketoacidosis | News

DKA risk increased with SGLT2 inhibitor use, but low overall

A large population-based study supports an increased risk for diabetic ketoacidosis for users of SGLT2 inhibitors compared with DPP-4 inhibitors, although the absolute risk remains low.

06-30-2020 | Medications | News

Network meta-analysis highlights research gaps for diabetes medications

A wide-ranging network meta-analysis published in the Annals of Internal Medicine reveals critical knowledge gaps in the use of glucose-lowering medications in people with type 2 diabetes.

06-29-2020 | SGLT2 inhibitors | News

CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

The latest CVD-REAL 2 data confirm clinical trial findings by showing that SGLT2 inhibitors significantly lower cardiovascular disease risk in people with type 2 diabetes, this time in comparison with DPP-4 inhibitors.

Themed collections

05-22-2017 | Heart failure | Themed collection | Collection

Heart failure and diabetes mellitus

This collection provides an overview of the epidemiology, underlying pathophysiological mechanisms, screening, assessment and management of heart failure in patients with diabetes mellitus.

Journal articles and book chapters

08-16-2018 | DPP-4 inhibitors | Review | Article

Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z


A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.


Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits